Identification of necroptosis-related lncRNAs for prognosis prediction and screening of potential drugs in patients with colorectal cancer

Table 1 Clinical characteristics of the colorectal cancer patients included in this study

Characteristics	TCGA-CRC (n = 537)			Clinical-CRC (n = 121)
	All	High risk (n = 269)	Low risk (n = 268)
Age
≤ 65	234 (43.58%)	114 (42.38%)	120 (44.78%)	53 (43.8%)
> 65	303 (56.42%)	155 (57.62%)	148 (55.22%)	68 (56.2)
Sex
Male	287 (53.45%)	141 (52.42%)	146 (45.48%)	61 (50.41%)
Female	250 (46.55%)	128 (47.58%)	122 (45.52%)	60 (49.29%)
T Stage
T1	15 (2.94%)	8 (2.97%)	7 (2.61%)	3 (2.48%)
T2	93 (17.32%)	42 (15.61%)	51 (19.03%)	17 (14.05%)
T3	366 (68.16%)	180 (66.91%)	186 (69.40%)	49 (40.5%)
T4	63 (11.73%)	39 (14.50%)	24 (8.96%)	52 (42.98%)
N Stage
N0	316 (58.85%)	140 (52.04%)	176 (65.67%)	67 (55.37%)
N1	128 (23.84%)	67 (24.91%)	61 (22.76%)	31 (25.62%)
N2	92 (17.13%)	62 (23.05%)	30 (11.19%)	23 (19.01%)
Unknown	1 (0.19%)	0	1 (0.38%)	-
M Stage
M0	400 (74.49%)	190 (70.63%)	210 (78.36%)	102 (84.3%)
M1	75 (13.97%)	46 (17.1%)	29 (10.82%)	19 (15.7%)
Unknown	62 (11.55%)	33 (12.27%)	29 (10.82%)	-
Stage
Stage I	93 (17.32%)	41 (15.24%)	52 (19.40%)	20 (16.53%)
Stage II	209 (38.92%)	91 (33.83%)	118 (44.03%)	42 (34.71%)
Stage III	149 (27.75%)	83 (30.86%)	66 (24.63%)	40 (33.06%)
Stage IV	76 (14.15%)	47 (17.47%)	29 (10.82%)	19 (15.7%)
Unknown	10 (1.86%)	7 (2.6%)	3 (1.12%)	-

TCGA: The Cancer Genome Atlas; CRC: Colorectal cancer.